Aqemia

Paris, France Founded: 2019 • Age: 7 yrs
Therapeutic molecules are discovered through AI and quantum physics integration.
Request Access

About Aqemia

Aqemia is a company based in Paris (France) founded in 2019 by Maximilien Levesque.. Aqemia has raised $102.82 million across 5 funding rounds from investors including Eurazeo, Bpifrance and Wendel. Aqemia offers products and services including AI Drug Discovery Platform and Quantum Physics Algorithms. Aqemia operates in a competitive market with competitors including NTxBio, Nimble Therapeutics, Applied BioMath, Enveda and IMIDomics, among others.

  • Headquarter Paris, France
  • Founders Maximilien Levesque
  • Sectors
    Healthcare
    Technology
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Technology → Artificial Intelligence & Machine Learning
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $102.82 M (USD)

    in 5 rounds

  • Latest Funding Round
    $7.4 M (USD), Grant

    Apr 01, 2025

  • Investors
    Eurazeo

    & 5 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Aqemia

Aqemia offers a comprehensive portfolio of products and services, including AI Drug Discovery Platform and Quantum Physics Algorithms. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Uses AI and quantum physics to generate drug candidates rapidly.

Algorithms that produce data for early-stage drug discovery projects.

People of Aqemia
Headcount 50-200
Employee Profiles 27
Employee Profiles
People
Maximilien Levesque
CEO and Co-Founder
People
Victor Noilhan
Research Scientist - In Silico Drug Discovery
People
Mathilde Batisse
RPO International Senior Talent Hunter @aqemia
People
Ingrid Delval
Chief of Staff

Unlock access to complete

Funding Insights of Aqemia

Aqemia has successfully raised a total of $102.82M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $7.4 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Grant — $7.4M
  • First Round

    (17 Oct 2019)

  • Investors Count 6
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2025 Amount Grant - Aqemia Valuation

investors

Dec, 2024 Amount Series A - Aqemia Valuation Cathay Innovation
Jan, 2024 Amount Series A - Aqemia Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Aqemia

Aqemia has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Eurazeo, Bpifrance and Wendel. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital investments are made in technology startups through a global ecosystem.
Founded Year Domain Location
Private equity and funds of funds focused on industrial, media, energy, healthcare, biotechnology, and multiple sectors
Founded Year Domain Location
Private equity and debt investments are managed across multiple sectors.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Aqemia

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Aqemia

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Aqemia Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Aqemia

Aqemia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NTxBio, Nimble Therapeutics, Applied BioMath, Enveda and IMIDomics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Provider of bio informatics platform to develops biologics and therapeutics
domain founded_year HQ Location
Combinatorial chemistry services for peptide-based drug discovery are provided.
domain founded_year HQ Location
Systems biology and pharmacology modeling services to aid drug discovery and development
domain founded_year HQ Location
Provider of AI-based platform to decipher the chemistry of nature and develop new medicines
domain founded_year HQ Location
Precision medicines for immune-mediated inflammatory diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Aqemia

When was Aqemia founded?

Aqemia was founded in 2019.

Where is Aqemia located?

Aqemia is headquartered in Paris, France.

Who is the current CEO of Aqemia?

Maximilien Levesque is the current CEO of Aqemia. They have also founded this company.

Is Aqemia a funded company?

Aqemia is a funded company, having raised a total of $102.82M across 5 funding rounds to date. The company's 1st funding round was a Series A of $32.49M, raised on Oct 17, 2019.

What does Aqemia do?

Aqemia was founded in 2019 in Paris, France, as a provider of AI-driven software combined with quantum physics for therapeutic molecule discovery. Small molecules are screened using AI-based technology to assess physical properties, supporting upstream processing and drug development. Therapeutic targets linked to specific diseases are identified. Operations focus on biotechnology and pharmaceuticals, aiding research in molecular screening and target validation across global collaborations.

Who are the top competitors of Aqemia?

Aqemia's top competitors include NTxBio, Enveda and Kvantify.

What products or services does Aqemia offer?

Aqemia offers AI Drug Discovery Platform and Quantum Physics Algorithms.

Who are Aqemia's investors?

Aqemia has 6 investors. Key investors include Eurazeo, Bpifrance, Wendel, unknown, and Cathay Innovation.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available